Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324555 · ClinicalTrials.gov registry record · Phase 1
Study of ORIC-101 in Healthy Adult Subjects
A Phase 1 study, sponsored by ORIC Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03324555 is a Phase 1 study that has completed, run by ORIC Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT03324555, a Phase 1 study, has completed, sponsored by ORIC Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
ORIC-GR-17001 is an open-label, single center, non-randomized, single ascending dose study in healthy male subjects and healthy female subjects of non-child bearing potential. In this study, ORIC-101 will be administered as single-ascending oral doses. The primary objective is to characterize the safety and tolerability of oral ORIC-101.
Interventions
- DRUG ORIC-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03324555
The ClinicalTrials.gov registry entry for NCT03324555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ORIC Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ORIC-101 is the first listed.
NCT03324555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03324555 about?
NCT03324555 is a clinical study titled "Study of ORIC-101 in Healthy Adult Subjects". ORIC-GR-17001 is an open-label, single center, non-randomized, single ascending dose study in healthy male subjects and healthy female subjects of non-child bearing potential. In this study, ORIC-101 will be administered as single-ascending oral doses. The primary objective is to characterize the sa...
What is the current status of trial NCT03324555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-10-19. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT03324555?
The interventions under investigation include: ORIC-101 (DRUG).
Who is sponsoring clinical trial NCT03324555?
This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.